‫منابع‬
[1]
Abdul A, Nelson F, Stanly Leonard R, Ramzis C, Pathologic Basis Of Disease, Ahmadi
N. 2005; 7th ed, Vol 2:128-132.
[2]
J.Marcdante K, Kleigman RM, B.Jenson H, E.Behrman R. Nelson essentials of
pediatrics.2011; 6th ed, Chap 155, Sec 21:595-597.
[3]
Pui CH, Relling MV. Acute lymphoblastic leukemia. New England J of Med.
2004;350:1535-48.
[4]
Pui CH, Evans W. Treatment of acute lymphoblastic leukemia. New England J of Med.
2006;354:166-78.
[5]
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al.
Erythropoietin or darbepoietin for patients with cancer. Cochran database Syet Rev. 2012;
2:21-25.
[6]
Macpherson L, Lindsay C, Reed N. Recombinant human epoietin beta in the treatment of
chemotherapy-related anemia. Therapeutics and clinical risk management. 2009;5:261270.
[7]
Kim M, Lee J, Wu C, Cho S, Lee K. Defective erythropoiesis in bone marrow in a
mechanism of anemia in children with cancer. J Korean med sci. 2002;17:337-40.
[8]
Shankar AG. The role of recombinant erythropoietin in childhood cancer. The oncologist.
2008;13:157-166.
[9]
Corazza F, Beguin Y, Bergmann P, et al. Anemia in children with cancer is associated
with decresed erythropoietic activity and not with in adequate erythropoietin production.
Blood. 1998;92:1793-98.
[10] Rodriguez JC, Beauchemin V, Villeneuve L, et al. Coordinate secretion of interleukin-1
beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute
myeloblastic leukemia:role of interleukin-1 as an endogenous inducer. Blood.
1990;76:1481-1489.
[11] Balkwill F, Osborne R, Burke F, et al. Evidence for tumor necrosis factor/cachectin
production in cancer. Lancet. 1987;28:1229-1232.
[12] Kremer JP, Reisbach G, Nerl C, et al. B-cell chronic lymphocytic leukemia cells express
and release transforming growth factor-beta. Br J Haematol. 1992;80:480-487.
[13] Dinndorf P, Seibel N, Mosher R, et al. Use of recombinant human erythropoietin to
minimize the needed for packed red blood cell transfusions in patients undergoing
therapy for localized osteogenic sarcoma with cisplatin,adriamycin regimen. Proc Am
Soc Pediatr Hematol Oncol. 1993;2:36.
[14] Dowd MD, Morgan ER, Langman CB, et al. serum erythropoietin levels in children with
leukemia. Med pediatr oncol. 1997;28:259-267.
[15] Kalmanti M, Kalmantis T. Committed erythroid progenitors and erythropoietin levels in
anemic children with lymphomas and tumor. Pediatr Hematol Oncol. 1989;6:85-93.
[16] Littlewood TJ. The efficacy of rHuEPO in cancer-related anemia. British J of Hematol.
2003;121:3-11.
[17] Tueffel O, Stanulla M, Cario G, Ludwig W, Rottger S, Schafer B, et al. Anemia and
survival in childhood acute lymphoblastic leukemia. Hematologica. 2008;93(11):165257.
[18] Santana VM, Dodge RK, Crist WM, Rivera GK, Look AT, Behm FG, et al. Presenting
features and treatment outcome of adolescent with acute lymphoblastic leukemia.
Leukemia. 1990;4:87-90.
[19] Reiter A, Schrappe M, Ludwig WD, Hiddeman W, Sauter S, Henze G, et al.
Chemotherapy in 998 unselected childhood lymphoblastic leukemia patients. Blood.
1994;84:3122-33.
[20] Donadieu J, Auclerc MF, Baruchel A, Leblance T, Landman J, Perel Y, et al. Critical
study of prognostic factors in childhood acute lymphoblastic leukemia:differences in
outcome are poorly explained by the most significant prognostic variables. Hematol.
1998;102:729-39.
[21] Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. Determinants of outcome
after intensified therapy of childhood lymphoblastic leukemia. Br J Haematol.
2001;113:103-14.
[22] Greaves MF, Janossy J, Peto J, Kay H. Immunologically defined subclasses of acute
lymphoblstic leukemia in children:their relationship to presentation features and
prognosis. Br J Haematol. 1981;48:179-97.
[23] Pullen DJ, Boyett JM, Crist WM, Falletta JM, Roper M, Dowell B, et al. Pediatric
oncology group utilization of immunologic markers in the designation of acute
lymphoblastic leukemia subgroups:influence on treatment response. Ann N Y Acad Sci.
1984;428:26-48.
[24] Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker
studies in childhood acute lymphoblastic leukemia. Blood. 1993;82:343-62.
[25] Cabanillas M, Kantarjian H, Thomas D, Mattiuzi G, Ritting M, Bruera E, et al. Epoietin
alpha decrease the number of erythrocyte transfusions in patients with acute
lymphoblastic leukemia,lymphoblastic lymphoma and burkitt leukemia/lymphoma.
Cancer. 2012;1:848-855.
[26] Arcasoy M. The non-hematopoietic biological effects of erythropoietin. British J of
hematology. 2008;141:14-31.
[27] Killian A. Pediatric use of recombinant human erythropoietin. A monthly newsletter for
health care from the childrens medical center at the university of Virginia. 2002;8(11):14.
[28] Silvia M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin
can promote erithroid progenitor survival by repressing apoptosis through Bcl-XL and
Bcl-2. Blood. 1996 Sep 1;88(5) : 1576-82.
[29] Huraib S, Abu-Aisha H, al-Momen A, al-Wakeel J, Memon N, al-Tuwaijri A. Effect of
recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in
hemodialysis patients. Am J Kidney Dis. 1997;29:866-70
[30] Graber SE, Krantz SB. Erythropoietin and tho control of red cell production. Annu Rev
Med. 1978;29: 51-66.
[31] Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and
expression of the human erythropoietin gene. Proc Nat Acad Sci USA. 1985;92:7850-84.
[32] Andrade L, Agentes estimulantes de la eritropoyesis. Rev Nefrol Dialisis Traspl.
2008;28(2):73-82.
[33] MarsdenJT. Agentes stimulates de la eritropoiesis. Rev Nephrol Dialisis Traspl.
2008;28:73-82.
[34] Eschbach JW, Abdulhadi MH, Brownie JK, Delano BG, Downing MR, Egrie JC, et al.
Reccombinant human erythropoietin in anemic patients with end-stage renal disease. Ann
Intern Med. 1989;111:992-1000.
[35] Ifudu O, Feldman J, Freidman EA. The intensity of hemodialysis and the response to
erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996;334:420-5.
[36] Singh A, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia
with epoietin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
[37] Ludwig H. Epoietin in cancer-related anemia. Nephrol Dial Transplant. 1999;14:85-92.
[38] Nowrousian M. Recombinant human erythropoietin in the prevention and treatment of
chemotherapy-induced anemia. Med Oncol. 1998;15:141-4.
[39] Jilani SM, Glapsy JA. Impact of epoietin alfa in chemotherapy-associated anemia.Semin
Oncol. 1998;25:571-6
[40] Rizzo JD, Somerfield MR, Hagerty KL, Seidenfel J, Bohlius J, Bannett CL,et al. Use of
epoietin and darbepoietin in patients with cancer. J Clin Oncol. 2008;26:132-49.
[41] Marec-Berard P, Chastagner P, Kassab D, Casadevall N, Marchal C, Misset JL, et al.
2007 standards, options and recommendations:use of erythropoiesis-stimulating agents
for the management of anemia in children with cancer. Pediatr Blood Cancer. 2009;53:712.
[42] Bennetts G, Bertolone S, Bray G, et al. Erythropoietin reduces volume of red cell
transfusion in some subset of children with acute lymphoblastic leukemia. Blood.
1995;10:853a.
[43] Csaki C, Ferencz T, Schuler D,et al. Recombinant human erythropoietin in the prevention
of chemotherapy-induced anemia in children with malignant solid tumors. Eur J Cancer.
1998;34:364-367.
[44] Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need
for erythrocyte and platelet transfusion in pediatric patients with sarcoma. J Pediatr.
1996;129:656-660.
[45] Henze G, Michon J, Morland B, et al. Phase III randomized study:Efficacy of epoietin
alfa in reducing blood tranafusions in newly diagnosed pediatric cancer patients receiving
chemotherapy. Proc Am Soc Clin Oncol. 2002;21:387a.
[46] Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind placebo controlled study of
quality of life,hematologic end points and safetly of weekly epoietin alfa in children with
cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24:3583-3589.
[47] Abdelrazik N, Fouda M. Once weekly recombinant human erythropoietin treatment for
cancer-induced anemia in children with acute lymphoblastic leukemia receiving
maintenance chemotherapy. Hematology. 2007;12:533-41.
[48] Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al.
Recombinant human erythropoietin therapy for anemic cancer patients on combination
chemotherapy. J Natl Cancer Inst. 1993;85(10):801-6.
[49] Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. .
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin
chemotherapy. Cancer J Sci AM. 1995;1(4):252-60.
[50] Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin
treatment for chemotherapy-related anemic in children. Pediatrics. 1999;103(2):E16.
[51] Lappin T, Maxwell AP, Johnston PG. Warming Flags for Erythropoiesis-Simulating
Agents and Cancer-Assosiated Anemia. Oncologist. 2007;12:362-5.
[52] Egrie JC, Browne JK. Development and characterization of novel erythropoiesis
simulating protein (NESP). Br J Cancer. 2001;84:3-10.
[53] Halstenson CE, Macres M, Katz SA et al. comparative pharmacokinetics and
pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50:702712.
[54] Steensma DP, Molina R, Sloan JA et al. Phase III study of two different dosing schedules
of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006;24:1079-1089.
[55] Glaspy J, Vadhan-Raj S, Patel R et al. Randomized comparison of every-2-week
darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced
anemia: The 20030125 Study Group Trial. J Clin Oncol. 2006;24:2290-2297.
[56] Burnham TH, ed. Drug Facts and Comparisons. St. Louis: Facts and Comparisons, Inc.
2002:135-8.
[57] Braun A, Ding R, Seidel C, et al. pharmacokinetics of recombinant human erythropoietin
applied subcutaneously to children with cheronic renal failure. Pediatr Nephrol.
1993;7:61-4.
[58] Ragni G, Clerico A, SordiA et al. Rrecombinant human erythropoietin (rHuEPO) in
children with cancer. A randomized study Med Pediatr Oncol. 1998;31:274.
[59] Buyukpamukcu M, Varan A, Kutluk T et al. Is epoetin alfa a treatment option foe
chemotherapy-related anemia in children? Med Pediatr Oncol. 2002;29:455-458.
[60] Bianchetti MG, Hammerli I, Roduit C et al. Eepoetin alfa in anemic children or
adolescents on regular dialysis. Eur J Pediatr. 1991;150:509-512.
[61] Matsumara M, Nomura H, Koni I, et al. Angiotensin-converting enzyme inhibitors are
associated with the need for increased recombinant human erythropoietin maintenance
doses in hemodialysis patients. Nephron. 1997;77:164-8.
[62] Durmaz O, Demirkaya M, Sevinir B. Recombinant human erythropoietin B:the effect of
weekly dosing on anemia,quality of life and long-term outcomes in pediatric cancer
patients. Pediatr hematol oncol. 2011;28(6):461-8.
[63] Vargas A, Mendoza I, Uranga R, Gonzalez A, Martinez L, Caballero I. Efficacy and
safety of iorEPOCIM for chemotherapy or radiotherapy induced anemia in pediatric
cancer patients. Medicc Review. 2010;12(3):27-31.
[64] Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A. Recombinant human
erythropoietin beta therapy:an effective strategy to reduce transfusion to requirement in
children receiving anticancer treatment. Pediatr Hematol Oncol. 2008;25(6):509-521.
[65] Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and
granulocyte colony-stimulating factor does not decrease blood transfusion requirement
during induction therapy for high-risk neuroblastoma:A randomized controlled trial. J
Clin Oncol. 2004;22:1886-1893.
[66] Leon P, Jimenez M, Barona P, Sierasesumaga L. Recombinant human erythropoietin for
the treatment of anemia in hildren with solid malignant tumors. Med Pediatr Oncol.
1998;30(2):110-6.
[67] Bolonaki I, Stiakaki E, Lydaki E, Dimitrion H, Kambourakis A, Kalmantis TH.
Treatment with recombinant human erythropoietin in children with malignancies. Oncol.
1996;13(2):111-121.
[68] Kliegman RM. Nelson Textbook of Pediatrics. 2011; Vol 3: 1732-36.
[69] Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant human
erythropoietin treatment in cisplatin-associated anemia: a randomized ,double-blind tril
with placebo. J Clin Oncol. 1994;12:1058-1062.
[70] Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment
of cisplatin –associated anemia. J Natl Cancer Inst. 1992;84:98-103.
[71] Dunphy FR.Dunleavy TL.Harrison BR. Erythropoietin reduces anemia and transfusions
after chemotherapy with paclitaxel and carboplatin . Cancer. 1997;79:1623-1628.
[72] Nenadov Beck M, beck D. Recombinant erythropoietin in acute chemotherapy-induced
anemia of children with ancer. Med Pediatr Oncol. 1995;25:17-21.
[73] Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with
recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9:2021-2026.
[74] Michon J. Incidence of anemia in pediatric cancer patients in Europe: Result of alarg,
international survey. Med Pediatr Oncol. 2002;39:448-450.
[75] Hellebostad M, Marstrander J, Slrdhl SH, Cotes M, Refsum HE. Serum immunoreactive
erythropoietin in children with acute leukemia. Eur J Haematol. 1990;44:159-163.
Abstract
Introduction: Anemia in children with cancer is a common disorder that has many causes .
One of the therapeutic approaches is the use of recombinant human erythropoietin that can
remove the anemia and Reduce the need for blood transfusion and its complications. Therefore,
this study aimed to investigate the effects of erythropoietin on the anemia associated with acute
lymphoblastic leukemia (ALL) in children .
Materials and methods: This study is analyticand clinical trial (RCT) On the 60 children
with ALL till done. Samples were randomly divided into two groups, control (n = 30 ) and
experimental group (n = 30 ) . The experimental group received150u / kg erythropoietin (Eprex)
and subcutaneously for 4 weeks. The data using the Chi-square test and t-test were analyzed in
software Spss ver.18 .
Findings: The mean age in the group treated with erythropoietin 6/46±3/23 and 6/73±3/27
years in the control group . In the present study , a significant association between baseline
hemoglobin and hemoglobin at the end of the study ( 4 weeks ) was observed(P.value=0.009).
While the frequency of blood transfusion during treatment were not significantly different in the
two treatment groups(P.value=0.20).
Conclusion: Based on the results of this study and comparison with other similar studies,
Erythropoietin can be a useful drug in the treatment of anemia associated with acute
lymphoblastic leukemia who were tolerated without any side effects in this study .Further
studies are needed to evaluating further complication.
Key words : erythropoietin , anemia , leukemia , children .
Islamic Azad Univercity
Branch Yazd
Medical school of Ali ebn abi taleb
A Thesis
Presented for Medical Degree (MD)
Title:
Effect of erythropoietin on the anemia associated with acute
lymphoblastic leukemia in children(1-15years)
Advisor:
Dr. Azam Hashemi
Supervisor:
Dr. Farzad Ferdosian
Statistical Supervisor:
Prof. Nasrollah Bashardoost
By:
Azadeh Seifadini
Summer 2013